Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds

New research indicates that individuals with both type 2 diabetes (T2D) and compromised immune systems may require multiple doses of the pneumococcal conjugate vaccine (PCV) to maintain sufficient protection. The findings highlight the potential need for adjusted vaccination strategies within this specific population. The study suggests that the standard single-dose PCV regimen may not provide adequate long-term immunity for immunocompromised individuals with T2D. Researchers observed that this group might benefit from a multi-dose schedule to ensure sustained protection against pneumococcal infections. The investigation focused on assessing the duration of vaccine-induced immunity in this vulnerable population.

Newsflash | Powered by GeneOnline AI
Date: April 19, 2025

Related posts:

Training in Future Thinking Proven to Reduce Impulsivity, Enhance Decision-Making Study Identifies Brain Circuits Linking Empathy to Behavioral Responses FDA Updates Generic Drug Approval Process with Streamlined ANDA Submissions and Enhanced Patent Transparency. Pharmacovigilance Crucial for Generic Drug Safety, Including Adverse Event Monitoring

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後